

ORIGINAL

TSCA NON-CONFIDENTIAL BUSINESS INFORMATION

DOCUMENT DESCRIPTION	DOCUMENT CONTROL NUMBER	DATE RECEIVED
8FHQ-06-16436	89100000281	7/21/10

COMMENTS:

DOES NOT CONTAIN CBI



RECEIVED
JUL 21 2010

10 JUL 21 AM 11:44

DuPont Haskell Global Centers
for Health and Environmental Sciences
1090 Elkton Road, P.O. Box 50
Newark, DE 19714-0050

July 20, 2010

Via Federal Express

8EHQ-0710-164360

Document Processing Center (Mail Code 7407M)
Room 6428
Attention: 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency, ICC Building
1201 Constitution Ave., NW
Washington, DC 20004



DCN: 89100000281



Dear 8(e) Coordinator:

8EHQ-06-16436/8EHQ-06-16478

This letter is a supplement to our letter of February 5, 2010 and summarizes the final results of a developmental toxicity study in rats with the above referenced test substance. This test substance is subject to a Consent Order, PMN P-08-509.

Groups of 22 time-mated CrI:CD(SD) rats were administered solutions of the test substance in deionized water at dose levels of 0, 10, 100, or 1000 mg/kg/day. Dosing was initiated on gestation day (GD) 6 and continued through GD 20. During the in-life portion of the study, maternal body weights and food consumption as well as clinical observations data were collected. On GD 21, dams were euthanized and underwent a gross external and internal examination. Weights for maternal livers and kidneys were recorded and these tissues were examined microscopically. The gravid uteri were removed, weighed, and dissected. Uterine contents were described and fetuses were counted, weighed, sexed, and examined for external, visceral, head, and skeletal alterations.

There was a dose-related increase in the number of dams found with early deliveries on GD 21. There were 0, 0, 4, and 9 dams found delivered at 0, 10, 100, and 1000 mg/kg/day, respectively. In addition, mean fetal weight was 8 and 28% lower (statistically significant) than controls at 100 and 1000 mg/kg/day, respectively. Maternal kidney weights were significantly higher at 1000 mg/kg/day and maternal liver weights were significantly higher at 100 and 1000 mg/kg/day. These changes were reported in the previous letter. The following is a complete summary of the study.

One female in the 1000 mg/kg/day was found dead on gestation day 20. This female had lower mean body weight gains and/or food consumption compared to the control group during gestation days 12-18. The test substance-related liver and kidney changes (moderate coagulative necrosis in the liver and fibrin thrombi in the glomerular capillaries) noted microscopically were considered the cause of death in this animal. Four and 9 females in the 100 and 1000 mg/kg/day groups, respectively, delivered early on gestation day 21. The mortality in the 1000 mg/kg/day group and early deliveries in the 100 and 1000 mg/kg/day groups were considered test substance-related. All other females survived to the scheduled necropsy.

Test substance-related clinical findings were noted in the 1000 mg/kg/day group and consisted of yellow material on various body surfaces and salivation or evidence thereof (clear material around the mouth). Mean body weight, mean body weight gain, mean food consumption, and mean gravid uterine weight in the 1000 mg/kg/day group were lower than control. At 100 mg/kg/day, mean gravid uterine weight was lower compared to control. An edematous pancreas was noted in 2 females that delivered early in the 1000 mg/kg/day group at necropsy; the relationship of this finding to the test substance is uncertain. Other macroscopic findings occurred in single females and/or are not uncommon in females that deliver. Higher mean liver weights were noted in the 100 and 1000 mg/kg/day group females, and higher mean kidney weight was observed in the 1000 mg/kg/day group. There were no microscopic correlates to the higher mean kidney weight. Focal necrosis of the liver was noted in some females in the 100 and

Contains No CBI

1000 mg/kg/day groups in a dose-related manner. In addition, test substance-related hepatocellular hypertrophy was noted at 1000 mg/kg/day; hypertrophy was morphologically consistent with a PPAR α agonist.

Mean fetal weights were 8.8% and 28.1% lower in the 100 and 1000 mg/kg/day groups, respectively. Intrauterine survival was not affected by test substance administration at any dosage level. There were no test substance-related fetal malformations. A higher mean litter proportion of 14th rudimentary ribs was observed in the 1000 mg/kg/day group, resulting in a higher mean litter proportion of total skeletal variations and total developmental variations. Although considered test substance-related, the increase in the number of fetuses with this finding was not considered adverse because it has been suggested that 14th rudimentary ribs are resorbed during postnatal development.

The no-observed-adverse-effect level (NOAEL) for maternal and developmental toxicity was considered to be 10 mg/kg/day based on mortality and lower mean body weight gains and food consumption at 1000 mg/kg/day and early deliveries, microscopic findings in the liver (focal necrosis), and lower mean fetal weights at 100 and 1000 mg/kg/day. At 1000 mg/kg/day, there were additional test substance-related effects that were not considered adverse and consisted of higher kidney and liver weights and hepatocellular hypertrophy.

This information is submitted in accordance with current guidance issued by EPA indicating EPA's interpretation of Section 8(e) of the Toxic Substances Control Act or, where it is not clear that reporting criteria have been met, it is submitted as a precautionary measure and because it is information in which EPA may have an interest.

Sincerely,

A handwritten signature in black ink that reads "A. Michael Kaplan". The signature is fluid and cursive, with a long horizontal stroke at the end.

A. Michael Kaplan, Ph.D.
Director - Regulatory Affairs

AMK/SMM: clp
(302) 366-5260

53
100

FedEx® US Airbill

Express

FedEx
Tracking
Number

8720 8907 5596

RECIPIENT: PEEL HERE

1 From This portion can be removed for Recipient's records.

Date 7-20-10 FedEx Tracking Number 872089075596

Sender's Name A. Michael Kaplan Phone 300 366-5260

Company DUPONT / GRAD / STINE HARKEL

Address 1090 ELKTON RD Dept./Floor/Suite/Room _____

City NEWARK State DE ZIP 19711-3507

2 Your Internal Billing Reference

3 To Recipient's Name Document Proc Ctr Phone 202 564-5940

Company WEPT, Room 6425, 11th Bldg

Address 1001 Constitution Ave, N.W. ☐ HOLD Weekday
We cannot deliver to P.O. boxes or P.O. ZIP codes
FedEx location address
REQUIRED, NOT available for
FedEx First Overnight.

Address _____ ☐ HOLD Saturday
FedEx location address
REQUIRED, Available ONLY for
FedEx Priority Overnight and
FedEx 2Day to select locations.

City Washington State DC ZIP 20004

0419275400



8720 8907 5596

Recipient's Copy

4a Express Package Service

* To most locations.

Packages up to 150 lbs.

☐ FedEx Priority Overnight
Next business morning * Friday
shipments will be delivered on Monday
unless SATURDAY Delivery is selected

☐ FedEx Standard Overnight
Next business afternoon *
Saturday Delivery NOT available

☐ FedEx First Overnight
Earliest next business morning
delivery to select locations *

☐ FedEx 2Day
Second business day ** Thursday
shipments will be delivered on Monday
unless SATURDAY Delivery is selected

☒ FedEx Express Saver
Next business afternoon *
Saturday Delivery NOT available.

EXP SAVER

4b Express Freight Service

** To most locations.

Packages over 150 lbs.

☐ FedEx 1Day Freight
Next business day ** Friday shipments will
be delivered on Monday unless SATURDAY
Delivery is selected

☐ FedEx 2Day Freight
Second business day ** Thursday shipments will be delivered
on Monday unless SATURDAY Delivery is selected

☐ FedEx 3Day Freight
Third business day ** Saturday Delivery NOT available

FedEx 1Day Freight Booking No. _____

5 Packaging

* Declared value limit \$500.

☐ FedEx Envelope* ☐ FedEx Pak*
Includes FedEx Small Pak and
FedEx Large Pak.

☐ FedEx Box ☐ FedEx Tube ☐ Other

6 Special Handling and Delivery Signature Options

☐ SATURDAY Delivery
NOT available for FedEx Standard Overnight, FedEx Express Saver, or FedEx 3Day Freight.

☐ No Signature Required
Package may be left without
obtaining a signature for delivery

☐ Direct Signature
Someone at recipient's address
may sign for delivery. Fee applies.

☐ Indirect Signature
If no one is available at recipient's
address, someone at a neighboring
address may sign for delivery. Fee applies.
for residential deliveries only.

Does this shipment contain dangerous goods?
One box must be checked

☐ No ☐ Yes
As per attached
Shipper's Declaration

☐ Yes
Shipper's Declaration
not required

☐ Dry Ice
Dry Ice, 8 UN 1845 _____ x _____ kg

Dangerous goods (including dry ice) cannot be shipped in FedEx packaging
or placed in a FedEx Express Drop Box

☐ Cargo Aircraft Only

7 Payment Bill to:

Enter FedEx Acct. No. or Credit Card No. below.

☒ Sender Acct. No. in Section 1 will be billed ☐ Recipient ☐ Third Party ☐ Credit Card ☐ Cash/Check

Total Packages _____ Total Weight _____ lbs.

Credit Card Auth. _____

Your liability is limited to \$100 unless you declare a higher value. See the current FedEx Service Guide for details.

605

fedex.com 1.800.GoFedEx 1.800.463.3339